Edition:
United Kingdom

Amarin Corporation PLC (AMRN.OQ)

AMRN.OQ on NASDAQ Stock Exchange Global Market

18.15USD
16 Nov 2018
Change (% chg)

$0.43 (+2.43%)
Prev Close
$17.72
Open
$18.10
Day's High
$18.19
Day's Low
$17.07
Volume
2,711,327
Avg. Vol
2,402,583
52-wk High
$23.33
52-wk Low
$2.36

Latest Key Developments (Source: Significant Developments)

Amarin Reports Q3 Loss Per Share Of $0.08
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Amarin Corporation PLC ::AMARIN REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON OPERATIONS.Q3 ADJUSTED NON-GAAP LOSS PER SHARE $0.06 EXCLUDING ITEMS.Q3 EARNINGS PER SHARE VIEW $-0.10 -- THOMSON REUTERS I/B/E/S.Q3 GAAP LOSS PER SHARE $0.08.QTRLY NET PRODUCT REVENUE FOR THREE MONTHS ENDED SEPTEMBER 30, 2018 AND 2017 WAS $55.0 MILLION AND $47.1 MILLION, RESPECTIVELY.PLANS TO SUBMIT SUPPLEMENTAL NDA IN EARLY 2019 SEEKING AN EXPANDED INDICATION FOR VASCEPA IN UNITED STATES.  Full Article

Amarin Reports Q2 GAAP Loss Of $0.12 Per Share
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Amarin Corporation PLC ::AMARIN REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON OPERATIONS.Q2 ADJUSTED NON-GAAP LOSS PER SHARE $0.10 EXCLUDING ITEMS.Q2 EARNINGS PER SHARE VIEW $-0.09 -- THOMSON REUTERS I/B/E/S.Q2 GAAP LOSS PER SHARE $0.12.QTRLY NET PRODUCT REVENUE $52.5 MILLION VERSUS $44.9 MILLION.  Full Article

Amarin Says Settlement Agreement Provides That Co Will Pay Teva $2 Mln
Thursday, 24 May 2018 

May 24 (Reuters) - Amarin Corporation PLC ::AMARIN CORPORATION SAYS SETTLEMENT AGREEMENT WITH TEVA PROVIDES THAT CO WILL PAY TEVA $2 MILLION - SEC FILING.AMARIN CORPORATION PLC - OTHER TERMS OF SETTLEMENT AGREEMENT WITH TEVA ARE CONFIDENTIAL.  Full Article

Amarin estimates net product revenue for Q1 to be about $43 mln
Wednesday, 4 Apr 2018 

April 4 (Reuters) - Amarin Corporation PLC ::AMARIN UPDATES FIRST QUARTER REVENUE GUIDANCE, REITERATES FULL YEAR GUIDANCE AND UPDATES ON REDUCE-IT CARDIOVASCULAR OUTCOMES STUDY PROGRESS AND VASCEPA PROMOTION INITIATIVES.ESTIMATES THAT NET PRODUCT REVENUE FOR ITS FIRST FISCAL QUARTER IS LIKELY TO BE APPROXIMATELY $43 MILLION.‍WITH RESPECT TO FY 2018 NET PRODUCT REVENUE EXPECTATIONS, CONTINUES TO BELIEVE ON TRACK TO ACHIEVE PRODUCT REVENUE OF AT LEAST $230 MILLION.​.  Full Article

Amarin Announces Proposed Public Offering Of American Depositary Shares
Monday, 29 Jan 2018 

Jan 29 (Reuters) - Amarin Corporation Plc ::AMARIN ANNOUNCES PROPOSED PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES.AMARIN CORPORATION PLC - ‍ANNOUNCED A REGISTERED UNDERWRITTEN PUBLIC OFFERING OF ITS AMERICAN DEPOSITARY SHARES​.AMARIN CORPORATION PLC - TO USE NET PROCEEDS FROM OFFERING TO EXPAND MEDICAL EDUCATION AND MARKET AWARENESS INITIATIVES.  Full Article

Amarin Corp Sees Full-Year 2017 Net Product Revenue Estimated Between $177 Mln-$180 Mln​
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Amarin Corp Plc ::AMARIN PROVIDES PRELIMINARY 2017 RESULTS AND PROVIDES 2018 OUTLOOK.AMARIN CORPORATION PLC SEES ‍UNAUDITED FULL-YEAR 2017 NET PRODUCT REVENUE ESTIMATED BETWEEN $177 AND $180 MILLION​.AMARIN - ‍WITHOUT ADJUSTMENT FOR IMPACT OF REDUCE-IT RESULTS, CO ESTIMATES 2018 NET PRODUCT REVENUE FROM VASCEPA WILL GROW TO ABOUT $230 MILLION​.AMARIN - ‍ESTIMATES IN EACH QUARTER OF 2018 NET PRODUCT REVENUE SHOULD GROW APPROXIMATELY 30% OR MORE AS COMPARED TO SAME QUARTER IN 2017​.AMARIN CORPORATION PLC - ‍ESTIMATES THAT ITS NET PRODUCT REVENUE IN Q1 2018 WILL BE BETWEEN $45 AND $48 MILLION​.AMARIN CORPORATION PLC - ‍ANTICIPATES THAT Q2 2018 RESULTS WILL REBOUND WITH NET PRODUCT REVENUE ANTICIPATED IN Q2 2018 OF $55 MILLION OR MORE​.  Full Article

Amarin Says It Is On Track To Report Top-Line Results From REDUCE-IT Cardiovascular Outcomes Study
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Amarin Corporation Plc ::AMARIN ANNOUNCES REDUCE-IT CARDIOVASCULAR OUTCOMES STUDY FINAL PATIENT VISITS TO COMMENCE IN MARCH 2018.AMARIN CORPORATION PLC - CONFIRMED IT IS ON TRACK TO REPORT TOP-LINE RESULTS FROM REDUCE-IT CARDIOVASCULAR OUTCOMES STUDY BEFORE END OF Q3 2018.AMARIN - ‍MAINTAINS GUIDANCE THAT ONSET OF TARGETED 1,612TH PRIMARY MACE IN STUDY IS PROJECTED TO OCCUR BEFORE END OF Q1 2018​.  Full Article

Amarin reports Q3 loss per share $0.04
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Amarin :Amarin reports third quarter 2017 financial results and provides update on operations.Q3 loss per share $0.04.Q3 earnings per share view $-0.05 -- Thomson Reuters I/B/E/S.Amarin Corporation Plc - Qtrly net product revenue $47.1 million versus $32.4 million​.  Full Article

Amarin names Mark Salyer chief commercial officer
Wednesday, 13 Sep 2017 

Sept 13 (Reuters) - Amarin Corporation Plc :Amarin appoints Mark W. Salyer to new position of chief commercial officer.Amarin remains on track to reach record product revenues of $165 to $175 million in 2017​.Most recently, Salyer was at Teva Pharmaceuticals as executive vice president and general manager of Teva Respiratory LLC​.  Full Article